Stock OGN ORGANON & CO.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Organon & Co.

Equities

OGN

US68622V1061

Market Closed - Nyse
Other stock markets
 16:00:02 2024-05-01 EDT 		5-day change 1st Jan Change
18.83 USD +1.18% Intraday chart for Organon & Co. +0.64% +30.58%
04-29 Piper Sandler Raiises Price Target on Organon to $24 From $22, Maintains Overweight Rating MT
04-09 Morgan Stanley Lifts Price Target on Organon to $18 From $17, Keeps Equalweight Rating MT

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
El estudio clínico comparativo de fase 3 del candidato a biosimilar de Prolia ® y Xgeva ® (denosumab) HLX14 alcanzó los criterios de valoración primarios
Klinische Phase-3-Vergleichsstudie zwischen Prolia ® und Xgeva ® (Denosumab) - Biosimilar-Kandidat HLX14 erreicht primäre Endpunkte
L'essai clinique comparatif de phase 3 du candidat biosimilaire de Prolia ® et de Xgeva ® (denosumab) HLX14 remplit les critères d'évaluation primaires
Shanghai Henlius Biotech Denosumab Biosimilar HLX14 Meets Endpoint
Aurobindo Pharma Gets US FDA Final Nod for Mometasone Furoate Monohydrate Nasal Spray
Philips : une nouvelle directrice financière en octobre
New York attorney general urges stronger safety warning on asthma drug Singulair
Organon's Hadlima Chosen by VA as Substitute for Humira
US Department of Veterans Affairs (VA) Selects Organon & Co.'s HADLIMA, Replacing HUMIRA on Its National Formulary
US Department of Veterans Affairs (VA) Selects Organon & Co.'s HADLIMA, Replacing HUMIRA on Its National Formulary
Sector Update: Health Care Stocks Edge Higher Premarket Thursday
Organon's Q4 Adjusted Earnings, Revenue Rise; 2024 Revenue Guidance Issued
Organon & Co. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023
Organon & Co. Declares Quarterly Dividend, Payable on March 14, 2024
Organon & Co. Provides Earnings Guidance for the Year 2024
Organon Says Xaciato Vaginal Gel 2% Now Available in the US via Prescription to Treat Bacterial Vaginosis
Organon?S Xaciato (Clindamycin Phosphate) Vaginal Gel 2% Available Nationwide to Treat Bacterial Vaginosis in Females Aged 12 and Older
Organon Affirms 2023 Revenue Outlook, Sets 2024 Guidance; Shares Jump
Organon et Lilly concluent un accord de commercialisation en Europe pour deux médicaments contre la migraine
Organon y Lilly suscriben acuerdo de comercialización para dos medicamentos contra la migraña en Europa
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. OGN Stock
  4. News Organon & Co.
  5. Other languages